Amgen Completes Five Prime Therapeutics Deal
socalTECH
APRIL 16, 2021
billion acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. per share in cash for Five Prime Therapeutics. Five Prime's programs include bemarituzumab, a Phase 3 trial-ready, first-in-class program for gastric cancer.
Let's personalize your content